TP53 is the most frequently mutated gene in breast cancer, but its role in survival is confounded by different studies concluding that TP53 mutations are associated with negative, neutral, or positive outcomes. Closer examination showed that many studies were limited by factors such as imprecise methods to detect TP53 mutations and small cohorts that combined patients treated with drugs having very different mechanisms of action. When only studies of patients receiving the same treatment(s) were compared, they tended to agree. These analyses reveal a role for TP53 in response to different treatments as complex as its different biological activities. We discuss studies that have assessed the role of TP53 mutations in breast cancer treatment and limitations in interpreting reported results.

TP53是乳腺癌中最常见的突变基因，但是其在存活中的作用被不同的研究所混淆，这些研究认为TP53突变与阴性，中性或阳性结果相关。进一步的检查显示，许多研究受到因素的限制，例如检测TP53突变的不精确方法以及将使用具有完全不同作用机理的药物治疗的患者合并在一起的小型队列。当仅比较接受相同治疗的患者的研究时，他们倾向于同意。这些分析揭示了TP53在响应像其不同的生物活性这样复杂的不同处理中的作用。我们讨论评估TP53作用的研究 乳腺癌治疗中的突变和解释报告结果的局限性。